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Abstract: A number of 1-(2-aminopropyl)-2-mercaptobenzimidazoles related to the TIBO derivative R82150 
have been prepared and tested for their activity against human immunodeficiency virus type 1 (HIV-l). These 
compounds were all modest inhibitors of the cytopathic effects of HIV-lin vitro, but only very weak inhibitors 
of HIV- 1 reverse transcriptase (RT). 
Treatment of infection by human immunodeficiency virus type 1 (HIV-l), the causative agent of AIDS? 
is currently limited to the nucleoside analogs 3’-azido-3’-deoxythymidine (AZT, zidovudine), 2’,3’-dideoxy- 
inosine (DDI. didanosine), and most recently 2’,3’-dideoxycytidine @DC, zalcitabme). These drugs suffer from 
a number of limitations, including toxic side effects3 and the emergence of drug-resistant strains of the viru~.~ 
Recently, non-nucleoside inhibitors of HIV-l reverse transcriptase (RT) have been reported, including the TIBO 
analog R82150 (1)5, nevirapine,b several 2-pyridinones,’ a series of uracil derivatives,* and some bis 
heteroarylpiperazines.9 Several of these non-nucleosides are active against HIV-l (but not HIV-2) in the 
nanomolar range in vitro. This structurally diverse group of compounds have a similar antiviral profile, and 
inhibit HIV-l RT via binding at an allosteric site, in contrast to active site inhibitors such as AZT.l” The 
structure-activity relationships of the TIBO series of compounds have been well investigated,” but all 
modifications have conserved the tricyclic ring system. We were interested in studying whether the diazepine 
ring was necessary in order to maintain activity against HIV-l. Either removal of the C-7 carbon, or scission of 
the C-7 to C-7a bond in the diazepine ring of the TIBO derivative 1, would lead to the 2- 
mercaptobenzimidazole derivatives 2c and 3c, respectively, which may be able to assume a TIBO-like conform- 
ation in the active site. In the present report, we describe the synthesis, cytotoxicity, and anti-HIV activity of 
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Scheme I illustrates the synthetic route used to prepare the target compounds 2a-c and 3a-c. Treatment 
of the commercially available 2-chlorobenzimidazole (4) with sodium hydride (1.2 equivalents) in 
dimethylformamide at room temperature provided the sodium salt, which was alkylated with chloroacetone (1.2 
equivalents) to afford the l-substituted compound 5 in 93% yield. Displacement of the halogen proceeded 
smoothly at 80“ C in methanolic sodium hydrogen sulfide (from 1.2 eqivalents sodium methoxide in methanol 
saturated with hydrogen sulfide) to give compound 6 in 8 1% yield. Reductive amination of the methyl ketone 6 
with sodium cyanoborohydride’a and an excess of the appropriate amine 1s in methanol at pH 7 gave a racemic 
mixture of the desired compounds WC. The free amines were purified by column chromatography on silica gel 
using either ethyl acetate/hexanes or methanol/chloroform as the mobile phase. Lyophilization of an acidified 
(with 1N HCl to pH=3) solution of the free amines in methanol/water provided the hydrochloride salts of 2a-c 
in 57-59% yields. The methylated products (3a-c) were prepared by treatment of the free amities 2a-c with 
excess formaldehyde and sodium cyanoborohydride in acetonitrile at pH 7, and then isolated as their 
hydrochloride salts after column chromatography.r4 
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The l-substituted benzimidazoles (2a-c and 3a-c) were evaluated for cytotoxicity and activity against 
HIV-l in CEM-SS cells.15 All compounds tested were modest inhibitors of HIV-1 syncytial plaque formation, 
and fifty percent inhibitory concentrations (K&J’s) ranged from 4 to 28 pM (Table I). Cytotoxicity was 
determined by measuring inhibition of [3H’&hymidine incorporation into DNA of uninfected cells. On this 
basis, all compounds exhibited a modest separation between antiviral activity and toxicity. Compounds 2a, 2c, 
and 3a had similar toxicities, with 50% cytotoxic concentrations (CC,) around 80 l.tM, while compounds 2b, 
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3b, and 3c were less toxic, not reaching a CC% at drug concentrations of 100 PM. Compound 2a was the most 
potent antiviral of the series, and had a selectivity index (CC&K.!~) of 19. 
In order to ascertain whether these compounds were acting as HIV-l RT inhibitors, compounds 2a-c. 3a, 
and 3c were tested for their activity against HIV- 1 RT using a ribosomal RNA template.‘6 Shown in Table I is 
the inhibition of HIV-l RT at a concentration of 10 pg/mL (approximately 30 PM), and at a concentration of 
100 pg/mL (approximately 300 PM). All compounds tested were weak inhibitors of HIV-l RT, even at 
concentrations higher than their in vitro ICse values. In fact, at drug concentrations as high as 100 pg/mL 
(approximately 300 PM), the IQ0 was not obtained. In contrast, the TIBO derivative R82913 (9-chloro 
derivative of 1) was highly active against HIV-l RT when tested as a positive control.t7 This dramatic 
difference in HIV-l RT inhibition between the TIBO derivative R82913 and the new benzimidazoles 
demonstrates that an intact diazepine ring appears to be necessary for inhibition of HIV- 1 RT by TIBO analogs. 
Furthermore, this minimal RT activity indicates that the modest in vitro anti-HIV-l activity of the new l- 
substituted mercaptobenzimidazoles is not solely due to the inhibition of HIV-l RT, and that these compounds 
might function via a different mechanism from other non-nucleosides active against HIV-l. To the best of our 
knowledge, the compounds 2a-c and 3a-c are the first benzimidazoles with activity against HIV-l at non-toxic 
concentrations. We are currently studying modifications of the N-l substituent, as well as halogenation of the 
benzimidazole moiety, with the intent of increasing the potency and selectivity of this series of compounds. 
Table I: Biological Activity of Some Substituted 2-Mercaptobenzimidazoles. 
Compound Substituent $0 RT Inhibitions 50% Inhibitory Concentration (pM)b 
Ri RZ 1OPglmL lOOl@AuL HIV-1c Cytotoxicityd 
2 
2: 
H c csI& 
C&!I-I=CH~ 
17 36 4.3 82 
H 4.5 29 
;: 
>lOO 
2c H 19 46 81 
3a f=3 
cH#I=C(cH& 
~2GJ% 13 79 
3b a3 cH2cH=cH2 NIY I% i! >lOO 
3c cH3 m2(==c@3)2 19 34 14 >loO 
R82150 ND ND 79 
R82913 ICs1~=0.005 &nL k&Z 35 
=‘Q Inhibition of HIV-l RT using a ribosomal RNA template versus control at the given concentration. 
bAverage of two or three experiments. Gyncytial assay in CEM-SS cells. d[sH]thymidine uptake inhibition in 
CEM-SS cells. knot determined. 
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